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FAST TIMES IN FEDERAL COURT 
AND THE NEED FOR FLEXIBILITY 
Hon. K. Michael Moore* 
 
As one might expect, the Southern District of Florida—once home to the 
“Cocaine Cowboys”—sees its fair share of narcotics cases.  The number of 
indictments alleging cocaine and marijuana possession and distribution 
remains steady, but there has recently been an increase in criminal 
prosecutions involving synthetic drugs. 
Synthetic drugs, also known as “New Psychoactive Substances,” are 
becoming alternatives to more commonplace drugs such as marijuana, 
cocaine, and heroin.1  Some of these substances are referred to as fentanyl, 
flakka,2 “spice,” MDMA, cannabinoids, or bath salts.3  The list goes on as 
new drugs are created and introduced to the market.  According to the U.S. 
Department of Justice’s Drug Enforcement Administration (DEA), law 
enforcement has encountered over three hundred different types of synthetic 
drugs.4  The Centers for Disease Control and Prevention (CDC) reported that 
between 2014 and 2015, the synthetic-opioid death rate increased by a 
staggering 72.2 percent.5  With the introduction of each new synthetic drug 
comes the challenge of identifying and criminalizing that particular 
substance. 
Designer drugs are commonly the result of ever so slightly altering the 
chemical compounds of existing or naturally produced narcotics.  There are 
three primary categories of synthetic drugs:  synthetic cannabinoids, 
synthetic cathinones, and synthetic phenethylamines.6  Synthetic 
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coauthored by Martha A. Leibell, judicial law clerk to the Honorable K. Michael Moore.  This 
Article was prepared for the Symposium on Forensic Expert Testimony, Daubert, and Rule 
702, held on October 27, 2017, at Boston College School of Law.  The Symposium took place 
under the sponsorship of the Judicial Conference Advisory Committee on Evidence Rules.  
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 1. See About Synthetic Drugs, DRUG ENFORCEMENT ADMIN., 
https://www.deadiversion.usdoj.gov/synthetic_drugs/about_sd.html [https://perma.cc/9W5G-
2ALY] (last visited Feb. 14, 2018). 
 2. Id.  “Flakka” is a psychoactive stimulant technically known as alpha-PVP. Id. 
 3. Id. 
 4. Id. 
 5. Synthetic Opioid Data, CENTERS DISEASE CONTROL & PREVENTION, 
https://www.cdc.gov/drugoverdose/data/fentanyl.html [https://perma.cc/U77J-DRFK] (last 
visited Feb. 14, 2018). 
 6. See About Synthetic Drugs, supra note 1. 
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cannabinoids are man-made chemicals that are packaged in two different 
forms for consumption:  (1) chemicals sprayed on dried and shredded plant 
material for smoking and (2) liquid form for vaporization and inhalation.7  
Synthetic cathinones are designed to mimic the pharmacological effects of 
cocaine, methamphetamine, and other stimulants.8  Synthetic 
phenethylamines are chemically produced drugs with hallucinogenic 
effects.9  One of several reasons for the rise in synthetic drugs was to avoid 
the classification of a particular substance as illicit and thereby evade 
criminal liability for possession and distribution. 
Over the past several decades, there have been numerous efforts to 
simplify the identification and criminalization of newly introduced or newly 
created narcotics.  The Controlled Substance Act of 1970 identified certain 
drugs and chemicals as controlled substances and divided them into 
schedules.  There are five schedules, with Schedule I substances being the 
most dangerous class of drugs and Schedule V the least. 
In 1986, Congress enacted the Controlled Substance Analogue 
Enforcement Act (the “Analogue Act”),10 which identifies substances that 
are substantially similar to those listed on the federal controlled substances 
schedules.11  As a result, a substance that is not listed as a Schedule I or II 
controlled substance receives the same treatment as a Schedule I or II 
controlled substance if (1) it shares a substantially similar chemical structure; 
(2) it has a stimulant, depressant, or hallucinogenic effect on the central 
nervous system that is substantially similar to or greater than the controlled 
substance; or (3) “with respect to a particular person, which such person 
represents or intends to have a stimulant, depressant, or hallucinogenic effect 
on the central nervous system that is substantially similar or greater than [the 
scheduled substance].”12 
In 2011, the Attorney General, through the Food and Drug Administration 
(FDA), placed five synthetic cannabinoids and three synthetic stimulants on 
Schedule I.13  The Synthetic Drug Abuse Prevention Act of 2012 added five 
structural categories of synthetic cannabinoids and eleven synthetic 
stimulants and hallucinogens to Schedule I.14  The Act also expanded the 
timeframe of temporary scheduling.15  Essentially, the Attorney General has 
the discretion, by order, to add a substance to Schedule I on a temporary basis 
if it is “necessary to avoid an imminent hazard to the public safety.”16 
 
 7. What Are Synthetic Cannabinoids?, NAT’L INST. ON DRUG ABUSE (Nov. 2015), 
https://www.drugabuse.gov/publications/drugfacts/synthetic-cannabinoids 
[https://perma.cc/6NDJ-JE7A]. 
 8. See About Synthetic Drugs, supra note 1. 
 9. Id. 
 10. Anti-Drug Abuse Act of 1986, Pub. L. No. 99-570, 100 Stat. 3207 (codified as 
amended at 21 U.S.C. § 813 (2012)). 
 11. See 21 U.S.C. § 802(32)(A) (2012). 
 12. Id. § 802(32)(A)(iii). 
 13. See LISA N. SACCO & KRISTIN FINKLEA, CONG. RESEARCH SERV., R42066, SYNTHETIC 
DRUGS:  OVERVIEW AND ISSUES FOR CONGRESS (2016). 
 14. 21 U.S.C. § 812(c) (2012). 
 15. Id. § 811(h)(2). 
 16. Id. § 811(h)(1). 
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The sentencing of individuals convicted of possession or distribution of 
synthetic drugs, particularly analogues that are not specifically listed on the 
schedules, is also working its way through the federal courts.  The U.S. 
Sentencing Commission (the Commission) is presently conducting a two-
year study of synthetic drugs.17  In April 2017, the Commission held a public 
hearing on the prevalence and effect of synthetic drugs and, since that 
hearing, began “a study of specific categories of synthetic drugs, including 
fentanyl.”18  The Commission is focusing on the “chemical structure, 
pharmacological effects, potential for addiction, legislative and scheduling 
history,” as well as other related issues.19 
The legislative approach to combating and criminalizing synthetic drugs is 
to provide a flexible framework.  The judiciary’s approach in addressing 
related evidentiary issues should be no different.  One way in which this need 
for malleability presents itself is in the admissibility of expert testimony.  
Rule 702 of the Federal Rules of Evidence and Daubert v. Merrell Dow 
Pharmaceuticals, Inc.20 provide the court, as the gatekeeper, with discretion 
regarding the admissibility of expert testimony. 
Rule 702 provides that an expert opinion is admissible if it is “based upon 
sufficient facts or data; the testimony is the product of reliable principles and 
methods; and the expert has reliably applied the principles and methods to 
the facts of the case.”21  In Daubert, the U.S. Supreme Court set forth factors 
for courts to consider in determining whether an expert’s methodology is 
sufficiently reliable:  (1) whether the methodology can and has been tested; 
(2) whether it has been subjected to peer review and publication; (3) what its 
known or potential rate of error is; and (4) its general acceptance in the 
field.22 
The application of Rule 702 and Daubert analysis is a frequent topic of 
debate.  Some suggest that Rule 702 should impose upon the courts more 
stringent standards for the admissibility of expert testimony.  One reason for 
doing so is that additional guidance in this area would assist judges who, 
more frequently than not, lack a background in the technical spheres in which 
expert testimony is proffered.  But maintaining the status quo and providing 
courts with a high level of discretion furthers the public’s interest in the swift 
administration of justice.  Synthetic-drug cases are but one example where 
adherence to rigid constructs would hinder prosecutions, perhaps 
significantly. 
Because these synthetic drugs are being altered at a rapid rate, it comes as 
no surprise that the defense of a criminal defendant will likely involve 
challenging the admissibility of expert testimony.  For example, while a 
 
 17. Press Release, U.S. Sentencing Comm’n, U.S. Sentencing Commission Announces 
2017–2018 Policy Work, Proposes Guideline Amendments:  Structural Reform and Synthetic 
Drugs Among Top Priorities (Aug. 17, 2017), https://www.ussc.gov/about/news/press-
releases/august-17-2017 [https://perma.cc/2YFL-6RNG]. 
 18. Id. 
 19. Id. 
 20. 509 U.S. 578 (1993). 
 21. FED. R. EVID. 702. 
 22. Daubert, 509 U.S. at 593–94. 
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chemist may employ sound testing procedures, the reliability of the chemist’s 
methodology might be called into question by a dearth of peer-reviewed 
articles.  Daubert provides much needed flexibility to gatekeepers in the 
emerging area of synthetic drugs. 
In 2015, I presided over a six-day jury trial that resulted in the conviction 
of a defendant on one count of conspiring to possess with intent to distribute 
controlled substances and controlled substance analogues.23  The defendant 
appealed his conviction arguing, in part, that the court clearly erred in finding 
that the most closely related substance referenced in the drug equivalency 
tables in the Sentencing Guidelines was THC, not marijuana.24  The 
defendant argued that the government’s expert’s opinions were not reliable 
because they were not based on human testing.25  The expert, whose 
testimony I admitted, opined on the effects of the alleged analogues on the 
human central nervous system and represented that his opinions were based 
on the structure of the chemicals, in vitro testing, in vivo testing in rodents, 
and case reports.26  The Eleventh Circuit affirmed and noted that the 
defendant’s objections went to the weight of the testimony, not the 
admissibility.27  This was a fairly straightforward case.  Because of the 
flexibility provided by Daubert, I considered the expert’s methodologies and 
reliability without being constrained by the lack of a particular kind of study 
or the lack of peer-reviewed articles, for example.  However, motions to 
exclude expert testimony are not always this clear cut. 
In 2013, in United States v. Fedida,28 Judge Roy Dalton of the Middle 
District of Florida addressed the reliability of the prosecution’s experts.  
There, the defendant was indicted for knowingly possessing and conspiring 
with others to knowingly possess UR-144,29 a controlled substance 
analogue.30  The government proffered testimony of expert witnesses who 
intended to opine on the pharmacologic effects of UR-144 and the substance 
to which it is analogous under the schedule—XLR-11.31 
At a hearing, the government’s experts opined that UR-144 and XLR-11 
have similar effects on the central nervous system.32  The court stated that 
these opinions were based on “little more than the experts’ review of the 
available scientific literature, which was limited to a few articles containing 
reports of UR-144’s binding affinity to cannabinoid receptors.”33  The court 
also noted that the experts’ opinions had not been subjected to peer review or 
 
 23. See United States v. Nahmani, 696 F. App’x 457, 461 (11th Cir. 2017). 
 24. Id. 
 25. Id. at 474. 
 26. Id. 
 27. Id. 
 28. 942 F. Supp. 2d 1270 (M.D. Fla. 2013). 
 29. UR-144 is a synthetic cannabinoid receptor. See WORLD HEALTH ORG., UR-144 
CRITICAL-REVIEW REPORT:  AGENDA ITEM 4.8, at 7 (2014), http://www.who.int/medicines/ 
areas/quality_safety/4_8_Review.pdf [https://perma.cc/F7P4-XZ2Y]. 
 30. Fedida, 942 F. Supp. 2d at 1271. 
 31. Id. at 1281. 
 32. Id. 
 33. Id. 
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publication.  Further, there was no evidence concerning the known or 
potential error rates of the experts’ methodology, which “amounted to little 
more than the deduction of a working hypothesis supported by a general 
knowledge of chemistry and biochemistry.”34  The court declined to rule on 
the issue of admissibility at that particular juncture but noted that it was not 
inclined to permit the expert testimony.35 
The shifting landscape of criminal prosecutions involving designer drugs 
presents several novel legal issues.  There are different ways to address these 
issues when they are the result of the production, possession, or distribution 
of as-of-yet unregulated substances.  One way is for the legislature to enact 
appropriate legislation as quickly as the need for regulation or criminalization 
arises—a lofty, if not unrealistic, goal.  The other is to guide the courts with 
general principles of applicability—the approach adopted by Congress 
through the enactment of the Analogue Act.36 
This small but unfortunately quickly expanding area of federal criminal 
law supports the notion that providing the courts with flexibility is necessary 
and ultimately consistent with the legislative approach in this field. 
 
 
 34. Id. 
 35. Id. at 1281–82. 
 36. 21 U.S.C. § 813 (2012). 
